Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Juvidex: Phase II data

The double-blind, U.K. Phase II RN1004-0082 trial in 195 patients showed that 300 and 600 mM Juvidex missed the primary endpoint of a

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE